Clinical interpretation of antinuclear antibody tests in systemic rheumatic diseases

Modern Rheumatology

Volumn 19, Issue 3, 2009, Pages 219-228

  Satoh, Minoru ^a   Vázquez Del Mercado, Monica ^b,c,d   Chan, Edward K L ^e  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b Insto de Investigacion en Reumatologia y del Sistema Musculo Esqueletico Sierra Mojada 950   (Mexico)

^c UNIVERSITY OF GUADALAJARA   (Mexico)

^d HOSPITAL CIVIL DE GUADALAJARA FRAY ANTONIO ALCALDE   (Mexico)

^e UNIVERSITY OF FLORIDA   (United States)

Author keywords

Antinuclear antibodies; Autoanti bodies; Polymyositis; Scleroderma; SLE

Indexed keywords

ANTINUCLEAR ANTIBODY; AUTOANTIBODY; CENTROMERE ANTIBODY; CYCLINE; DOUBLE STRANDED DNA ANTIBODY; FIBRILLARIN; JO 1 ANTIBODY; KU ANTIGEN; LA ANTIBODY; PHOSPHOLIPID ANTIBODY; RIBOSOMAL P ANTIBODY; RNA POLYMERASE III ANTIBODY; RO ANTIBODY; SIGNAL RECOGNITION PARTICLE; SM ANTIBODY; TOPOISOMERASE I ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY SCREENING; ANTIBODY SPECIFICITY; ANTIBODY TITER; ANTIPHOSPHOLIPID SYNDROME; CLINICAL EFFECTIVENESS; DERMATOMYOSITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HEP 2 CELL; HUMAN; IMMUNOPRECIPITATION; INTERSTITIAL LUNG DISEASE; MIXED CONNECTIVE TISSUE DISEASE; POLYMYOSITIS; PRIORITY JOURNAL; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SCLERODERMA; SENSITIVITY AND SPECIFICITY; SJOEGREN SYNDROME; SYNDROME CREST; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANTIBODIES, ANTINUCLEAR; BIOLOGICAL MARKERS; CONNECTIVE TISSUE DISEASES; HUMANS;

EID: 67349139617     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-009-0155-3     Document Type: Review

References (53)

1. Satoh M, Chan EKL, Sobel ES, Kimpel DL, Yamasaki Y, Narain S, et al. Clinical implication of autoantibodies in patients with systemic rheumatic diseases. Exp Rev Clin Immunol. 2007;3:721-38.
2. Tan EM, Feltkamp TE, Smolen JS, Butcher B, Dawkins R, Fritzler MJ, et al. Range of antinuclear antibodies in "healthy" individuals. Arthritis Rheum. 1997;40:1601-11.
3. Andrade LE, Chan EK, Peebles CL, Tan EM. Two major autoantigen-antibody systems of the mitotic spindle apparatus. Arthritis Rheum. 1996;39:1643-53.
4. Eystathioy T, Chan EK, Tenenbaum SA, Keene JD, Griffith K, Fritzler MJ. A phosphorylated cytoplasmic autoantigen, GW182, associates with a unique population of human mRNAs within novel cytoplasmic speckles. Mol Biol Cell. 2002;13:1338-51.
5. Jakymiw A, Lian S, Eystathioy T, Li S, Satoh M, Hamel JC, et al. Disruption of GW bodies impairs mammalian RNA interference. Nat Cell Biol. 2005;7:1267-74.
6. Jakymiw A, Pauley KM, Li S, Ikeda K, Lian S, Eystathioy T, et al. The role of GW/P-bodies in RNA processing and silencing. J Cell Sci. 2007;120:1317-23.
7. Jakymiw A, Ikeda K, Fritzler MJ, Reeves WH, Satoh M, Chan EK. Autoimmune targeting of key components of RNA interference. Arthritis Res Ther. 2006;8:R87.
8. Satoh M, Langdon JJ, Chou CH, McCauliffe DP, Treadwell EL, Ogasawara T, et al. Characterization of the Su antigen, a macromolecular complex of 100/102 and 200 kDa proteins recognized by autoantibodies in systemic rheumatic diseases. Clin Immunol Immunopathol. 1994;73:132-41.
9. Nozawa K, Fritzler MJ, Chan EK. Unique and shared features of Golgi complex autoantigens. Autoimmun Rev. 2005;4:35-41.
10. Yamasaki Y, Honkanen-Scott M, Hernandez L, Ikeda K, Barker T, Bubb MR, et al. Nucleolar staining cannot be used as a screening test for the scleroderma marker anti-RNA polymerase I/III antibodies. Arthritis Rheum. 2006;54:3051-6.
11. Buchanan RR, Riglar AG. The titre of anti-centromere antibodies: Its relationship to Raynaud's phenomenon and vascular occlusion. Br J Rheumatol. 1989;28:221-6.
12. Sharp GC, Irvin WS, May CM, Holman HR, McDuffie FC, Hess EV, et al. Association of autoantibodies to ribonucleoprotein and Sm antigens with mixed connective-tissue disease, systemic lupus erythematosus and other rheumatic diseases. N Engl J Med. 1976;295:1149-54.
13. Hoffman RW, Maldonado ME. Immune pathogenesis of mixed connective tissue disease: A short analytical review. Clin Immunol. 2008;128:8-17.
14. Bodolay E, Csiki Z, Szekanecz Z, Ben T, Kiss E, Zeher M, et al. Five-year follow-up of 665 Hungarian patients with undifferentiated connective tissue disease (UCTD). Clin Exp Rheumatol. 2003;21:313-20.
15. Mosca M, Tani C, Bombardieri S. Undifferentiated connective tissue diseases (UCTD): A new frontier for rheumatology. Best Pract Res Clin Rheumatol. 2007;21:1011-23.
16. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25:1271-7.
17. Reeves WH, Satoh M, Richards HB. Origins of antinuclear antibodies. In: Lahita RG, editor. Systemic lupus erythematosus, 4th ed. San Diego: Academic Press, 2004:401-31.
18. Reeves WH, Narain S, Satoh M. Autoantibodies in systemic lupus erythematosus. In: Koopman WJ, Moreland LW, editors. Arthritis and allied conditions. A textbook of rheumatology, 15th ed. Philadelphia: Lippincott Williams and Wilkins, 2005:1497-521.
19. Karassa FB, Afeltra A, Ambrozic A, Chang DM, De Keyser F, Doria A, et al. Accuracy of anti-ribosomal P protein antibody testing for the diagnosis of neuropsychiatric systemic lupus erythematosus: An international meta-analysis. Arthritis Rheum. 2006;54:312-24.
20. Okano Y, Steen VD, Medsger TAJ. Autoantibody reactive with RNA polymerase III in systemic sclerosis. Ann Intern Med. 1993;119:1005-13.
21. Kuwana M, Kaburaki J, Mimori T, Tojo T, Homma M. Autoantibody reactive with three classes of RNA polymerases in sera from patients with systemic sclerosis. J Clin Invest. 1993;91:1399-404.
22. Satoh M, Ajmani AK, Ogasawara T, Langdon JJ, Hirakata M, Wang J, et al. Autoantibodies to RNA polymerase II are common in systemic lupus erythematosus and overlap syndrome. Specific recognition of the phosphorylated (IIO) form by a subset of human sera. J Clin Invest. 1994;94:1981-9.
23. Steen VD. The many faces of scleroderma. Rheum Dis Clin North Am. 2008;34:1-15.
24. Fritzler MJ, Kinsella TD. The CREST syndrome: A distinct serologic entity with anticentromere antibodies. Am J Med. 1980;69:520-6.
25. Gelber AC, Pillemer SR, Baum BJ, Wigley FM, Hummers LK, Morris S, et al. Distinct recognition of antibodies to centromere proteins in primary Sjogren's syndrome compared with limited scleroderma. Ann Rheum Dis. 2006;65:1028-32.
26. Hayashi N, Koshiba M, Nishimura K, Sugiyama D, Nakamura T, Morinobu S, et al. Prevalence of disease-specific antinuclear antibodies in general population: Estimates from annual physical examinations of residents of a small town over a 5-year period. Mod Rheumatol. 2008;18:153-60.
27. Kuwana M, Kimura K, Hirakata M, Kawakami Y, Ikeda Y. Differences in autoantibody response to Th/To between systemic sclerosis and other autoimmune diseases. Ann Rheum Dis. 2002;61:842-6.
28. Fischer A, Pfalzgraf FJ, Feghali-Bostwick CA, Wright TM, Curran-Everett D, West SG, et al. Anti-Th/To-positivity in a cohort of patients with idiopathic pulmonary fibrosis. J Rheumatol. 2006;33:1600-5.
29. Okano Y. Antinuclear antibody in systemic sclerosis (scleroderma). Rheum Dis Clin North Am. 1996;22:709-35.
30. Medsger TAJ. Systemic sclerosis (scleroderma): Clinical aspects. In: Koopman WJ, editor. Arthritis and allied conditions. A textbook of rheumatology, 14th edn. Philadelphia: Lippincott Williams and Wilkins, 2001:1590-624.
31. Steen VD. Autoantibodies in systemic sclerosis. Semin Arthritis Rheum. 2005;35:35-42.
32. Hirakata M. Humoral aspects of polymyositis/dermatomyositis. Mod Rheumatol. 2000;10:199-206.
33. Mimori T, Imura Y, Nakashima R, Yoshifuji H. Autoantibodies in idiopathic inflammatory myopathy: An update on clinical and pathophysiological significance. Curr Opin Rheumatol. 2007;19:523-9.
34. Yoshida S, Akizuki M, Mimori T, Yamagata H, Inada S, Homma M. The precipitating antibody to an acidic nuclear protein antigen, the Jo-1, in connective tissue diseases. Arthritis Rheum. 1983;26:604-11.
35. Hirakata M, Suwa A, Takada T, Sato S, Nagai S, Genth E, et al. Clinical and immunogenetic features of patients with autoantibodies to asparaginyl-transfer RNA synthetase. Arthritis Rheum. 2007;56:1295-303.
36. Takada T, Hirakata M, Suwa A, Kaneko Y, Kuwana M, Ishihara T, et al. Clinical and histopathological features of myopathies in Japanese patients with anti-SRP autoantibodies. Mod Rheumatol. 2008; in press.
37. Cavazzana I, Ceribelli A, Quinzanini M, Scarsi M, Airo P, Cattaneo R, et al. Prevalence and clinical associations of anti-Ku antibodies in systemic autoimmune diseases. Lupus. 2008;17:727-32.
38. Rubin RL. Enzyme-linked immunosorbent assay for anti-DNA and antihistone antibodies including anti-(H2A-H2B). In: Rose NR, de Macario EC, Fahey JL, Friedman H, Penn GM, editors. Manual of clinical laboratory immunology, 4th ed. Washington, DC: American Society for Microbiology, 1992;735-40.
39. Targoff IN. Laboratory testing in the diagnosis and management of idiopathic inflammatory myopathies. Rheum Dis Clin North Am. 2002;28:859-90, viii.
40. Kuwana M, Okano Y, Pandey JP, Silver RM, Fertig N, Medsger TA Jr. Enzyme-linked immunosorbent assay for detection of anti-RNA polymerase III antibody: Analytical accuracy and clinical associations in systemic sclerosis. Arthritis Rheum. 2005;52:2425-32.
41. Kuwana M, Kimura K, Kawakami Y. Identification of an immunodominant epitope on RNA polymerase III recognized by systemic sclerosis sera: application to enzyme-linked immunosorbent assay. Arthritis Rheum. 2002;46:2742-7.
42. Santiago M, Baron M, Hudson M, Burlingame RW, Fritzler MJ. Antibodies to RNA polymerase III in systemic sclerosis detected by ELISA. J Rheumatol. 2007;34:1528-34.
43. Parker JC, Burlingame RW, Webb TT, Bunn CC. Anti-RNA polymerase III antibodies in patients with systemic sclerosis detected by indirect immunofluorescence and ELISA. Rheumatology (Oxf). 2008;47:976-9.
44. Reeves WH, Satoh M, Lyons R, Nichols C, Narain S. 2006. Detection of autoantibodies against proteins and ribonucleoproteins by double immunodiffusion, immunoprecipitation, and western blotting. In: Rose NR, Hamilton RG, Detrick B, Reeves WH, editors. Manual of molecular and clinical laboratory immunology, 7th ed. Washington, DC: American Society of Microbiology Press, 2006:1007-18.
45. Yamasaki Y, Narain S, Yoshida H, Hernandez L, Barker T, Hahn PC, et al. Autoantibodies to RNA helicase A: A new serological marker of early lupus. Arthritis Rheum. 2007;56:596-604.
46. Bonilla E, Francis L, Allam F, Ogrinc M, Neupane H, Phillips PE, et al. Immunofluorescence microscopy is superior to fluorescent beads for detection of antinuclear antibody reactivity in systemic lupus erythematosus patients. Clin Immunol. 2007;124:18-21.
47. Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med. 2003;349:1526-33.
48. Reimer G, Rose KM, Scheer U, Tan EM. Autoantibody to RNA polymerase I in scleroderma sera. J Clin Invest. 1987;79:65-72.
49. Takasaki Y, Yamanaka K, Takasaki C, Matsushita M, Yamada H, Nawata M, et al. Anticyclic citrullinated peptide antibodies in patients with mixed connective tissue disease. Mod Rheumatol. 2004;14:367-75.
50. Kakumanu P, Yamagata H, Sobel ES, Reeves WH, Chan EKL, Satoh M. Patients with pulmonary tuberculosis are frequently positive for anti-cyclic citrullinated peptide antibodies but also react with unmodified arginine-containing peptide. Arthritis Rheum. 2008;58:1576-81.
51. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al. Classification criteria for Sjogren's syndrome: A revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002;61:554-8.
52. McCauliffe DP, Wang L, Satoh M, Reeves WH, Small D. A recombinant 52 kD Ro (SS-A) ELISA detects autoantibodies in Sjogren's syndrome sera that go undetected by conventional serologic assays. J Rheumatol. 1997;24:860-6.
53. Nozawa K, Ikeda K, Satoh M, Reeves WH, Stewart CA, Li YC, et al. Autoantibody to nuclear antigen NA14 is an independent marker primarily for Sjögren's syndrome. Front Biosci. 2009;14:3733-9.